Today's Date: August 5, 2021
Vericast Back-to-School Survey Finds Parents Eager to Spend   •   13th Floor Entertainment Group Brings Haunted House Thrills to The Old Joliet Haunted Prison   •   Jimmy Placa of Davion Inc. Wins EY Entrepreneur of the Year 2021 New Jersey Award   •   Simplex Health Launches FITNatal   •   SYNLawn® Hosts Hundreds of Guests at "Farmers on the Green" STEM Educational Event at Boys and Girls Club of Harlem   •   WiSci Morocco Girls STEAM Camp Kicks Off Virtually August 9   •   5W Public Relations Continues Expansion of Parent, Child, & Baby PR Practice Area   •   New Amsterdam FC Announces Hofstra Soccer Stadium As Home Venue For Fall 2021 Season   •   United Way of Metro Chicago announces United Neighborhoods Equity Fund   •   New agreement to strengthen the early learningand child care system in Quebec   •   Pacific Airshow Amps Up the Thrills with New Afterburner Music Festival   •   Jeunesse Awarded 7 Globee Awards in 2021 Golden Bridge Competition   •   For First Time in TV History, Combate Global Knocks Out the UFC Competition   •   HITN, Teachley and Sirius Thinking to Produce Game-Changing Narratives for Bilingual Math Education   •   Open Mortgage Appoints Windi Gerber as Senior Vice President of Human Resources   •   Karma and Luck Celebrates Childhood Curiosity and Spirituality with First-Ever Children's Collection   •   Texas Original Compassionate Cultivation Drives Over 180,000 Miles to Deliver Medical Cannabis Across Texas   •   P&G Puts Athletes Who Lead with Love Center Stage at Olympic Games Tokyo 2020, Celebrating Their Efforts and Inspiring Posit   •   Greenwood Launches Greenwood Studio to Produce Finance and Business Shows and Podcasts for Black and Latino Audience   •   Regions Next Step Expands Financial Wellness Offerings for Students via iGrad and WeAreTeachers Platforms
Bookmark and Share

LogicBio Announces Presentation of Retrospective Study of Disease Course in Pediatric Patients with Severe Methylmalonic Acidemi

LogicBio Announces Presentation of Retrospective Study of Disease Course in Pediatric Patients with Severe Methylmalonic Acidemia

- Data presented at ACMG meeting evaluate disease progression in non-transplanted patients and children receiving liver transplantation

PR Newswire

LEXINGTON, Mass., May 3, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today announced results from a retrospective study of the disease course in pediatric patients living with severe methylmalonic acidemia (MMA) caused by a deficiency of the mitochondrial enzyme methylmalonyl-CoA mutase (MMUT). The study results were recently highlighted in a poster presentation at the American College of Medical Genetic and Genomics (ACMG) Annual Clinical Genetics Meeting.

MMA is a rare genetic disorder that can be caused by mutations in several genes, with the MMUT genetic mutation being the most common. Mutations in this gene, which provides instructions for making the MMUT enzyme, prevents the body from properly processing certain fats and proteins and can lead to the toxic buildup of methylmalonic acid and other disease-causing metabolites. Patients with severe MMA may present with symptoms as early as at birth including poor feeding, vomiting, hypotonia, hypothermia, respiratory distress and progressive encephalopathy. They are also at increased risk of neurological symptoms, failure to thrive, intellectual disability, severe infections and progressive renal insufficiency. There are currently no approved treatment options targeting the underlying cause of the disease. Current standard of care for MMA includes protein diet management and liver transplantation.

The retrospective non-interventional natural history study collected data via chart review from 18 patients diagnosed with severe MMA by newborn screening, including patients managed medically from birth to three years old (cohort 1) and pediatric-age recipients of liver transplant (cohort 2). Patients in cohort 2 were observed for the one-year period before liver transplantation and up to three years following the procedure. Results showed a significant and sustained decrease in methylmalonic acid levels post-transplantation compared to baseline levels. While levels did not approach normalization, there was an apparent reduction in variability, a potential indication of improved metabolic stability. Results indicate there were no significant differences in MMA- or transplant-related emergency room (ER) visits, stays or hospitalizations among patients pre- and post-transplantation up to three years. However, interpretation of the data on healthcare use was limited, as data for two and three years post-transplant were available for only one or two patients.

"Findings from this study are consistent with published clinical data supporting liver transplantation as an increasingly utilized therapeutic option for severe MMA patients while highlighting its limitations as an invasive and high-risk procedure that presents lifelong health considerations for patients," said Daniel Gruskin, M.D., senior vice president and head of clinical development at LogicBio. "These data help provide a better understanding of the natural progression and burden of this devastating rare disease and will help inform our clinical trial design and endpoint selection for future studies of our lead program LB-001. We also anticipate that results from a prospective natural history study we are initiating will provide important additional information about the disease course and position us to provide optimal support to families affected by MMA."

A link to the ACMG meeting study presentation is available under the "Events and Presentations" section of LogicBio's website, found here:

About Methylmalonic Acidemia (MMA)

Methylmalonic acidemia, or MMA, is a rare and life-threatening genetic disorder, affecting 1 in 25,000 to 50,000 newborns. In the most common form of MMA, a mutation in a gene called MMUT prevents the body from properly processing certain fats and proteins. As a result, toxic metabolites accumulate in the liver, in muscle tissue and in the brain. Symptoms include vomiting, lethargy, seizures, developmental delays and organ damage. There is no cure for MMA. To manage the symptoms, patients go on a severely restrictive, low-protein, high-calorie diet, often through a feeding tube. Even with aggressive management, these patients often experience life-threatening metabolic crises that can cause permanent neurocognitive damage.

About LogicBio Therapeutics, Inc.

LogicBio Therapeutics is a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood. The company's proprietary GeneRide™ platform is a new approach to precise gene insertion that harnesses a cell's natural DNA repair process leading to durable therapeutic protein expression levels. LogicBio's cutting-edge sAAVy™ capsid development platform is designed to support development of treatments in a broad range of indications and tissues. The company is based in Lexington, MA. For more information, visit

Media Contacts:

Bill Berry

Berry & Company Public Relations

W: 212-253-8881

C: 917-846-3862

Jenna Urban

Berry & Company Public Relations

W: 212-253-8881

C: 203-218-9180

Investor Contacts:

Matt Lane

Gilmartin Group



Cision View original content:

SOURCE LogicBio Therapeutics, Inc.

Back to top
| Back to home page

White House Live Stream
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Sounds Make the News ®
Atlanta - WAOK-Urban
Berkley / San Francisco - KPFA-Progressive
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
Washington - WOL-Urban

Listen to United Natiosns News